FDA has previously granted neridronate with Breakthrough Therapy, Fast Track, and Orphan Drug designations IRVINE, Calif., June 08, 2026 (GLOBE NEWSWIRE) -- Ambros Therapeutics, Inc. today announced ...
Complex Regional Pain Syndrome (CRPS) is a chronic and debilitating pain disorder, typically considered lifelong with limited treatment options. Now, new research finds that early detection and ...
Two out of three adults diagnosed with complex regional pain syndrome (CRPS) will experience new or worsening migraines, with one in five patients suffering near-daily headaches. A new study from ...
Complex Regional Pain Syndrome (CRPS) is a chronic and debilitating pain disorder, typically considered lifelong with limited treatment options. Now, groundbreaking research finds that early detection ...
According to the Company, a phase 2 trial will begin enrollment by the end of 2025. The Food and Drug Administration (FDA) has granted Orphan Drug designation to BRC-002 for the treatment of complex ...
Ambros Therapeutics, Inc. today announced that the first patient has been dosed in its pivotal CRPS-RISE Phase 3 clinical trial evaluating neridronate versus placebo for the treatment of Complex ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results